Brain Pulse Test Reveals Hidden Cognitive Deficits in Depression

Depression has long been described as a disorder of mood, but clinicians and researchers have increasingly recognized that it is also a disorder of thinking. Many people with major depressive disorder struggle with slowed processing, lapses in attention, and difficulty switching between tasks, and these cognitive problems can linger even after sadness lifts. A new study published in BMC Psychiatry by Jia-Qi Zhang, Hong-Guang Zhang, and colleagues at Zhejiang University School of Medicine and partner institutions now offers a fresh window into that struggle. By combining precise cognitive testing with a technique that directly probes the electrical response of the prefrontal cortex, the team has identified a measurable brain signature that tracks one of the most disabling features of depression: impaired sustained attention.

The research focused on the left dorsolateral prefrontal cortex, a region tucked into the upper outer portion of the frontal lobes that serves as a hub for cognitive control. This area is heavily involved in planning, working memory, attention regulation, and the flexible redirection of thought when circumstances change. It is also the most common target for repetitive transcranial magnetic stimulation, an approved treatment for treatment-resistant depression. Despite its clinical importance, researchers have lacked objective, neurophysiological markers that connect dysfunction in this region to the specific cognitive impairments seen in patients. The new study set out to fill that gap by asking a deceptively simple question: when you stimulate the left dorsolateral prefrontal cortex and record the brain’s immediate electrical reply, does that reply differ in people with depression, and does it relate to how well they think?

To answer it, the team recruited seventy-nine participants: forty-nine individuals diagnosed with major depressive disorder and thirty healthy controls. Each participant completed a comprehensive clinical assessment along with a battery of executive-function tests spanning multiple cognitive domains, including processing speed, sustained attention, cognitive flexibility, task switching, and the ability to inhibit responses during emotional conflict. The researchers then applied single-pulse transcranial magnetic stimulation over the left dorsolateral prefrontal cortex while simultaneously recording brain activity with electroencephalography, a paired technique known as TMS-EEG. The stimulation was delivered at the F3 scalp position, and the resulting TMS-evoked potentials were measured directly at that electrode, yielding a series of characteristic deflections labeled P30, N45, P60, N100, and P180 according to their polarity and timing in milliseconds after the pulse.

The behavioral results confirmed what prior clinical literature has suggested. Compared with healthy controls, patients with depression performed significantly worse across several domains: they were slower on processing-speed measures, showed reduced sustained attention, struggled more with cognitive flexibility and task switching, and had greater difficulty exerting inhibitory control when faced with emotionally conflicting information. These deficits were not confined to a single test but formed a coherent pattern of multidomain executive dysfunction, reinforcing the view that depression’s cognitive burden is broad rather than narrow, and that it touches the very machinery of self-regulation that people rely on in work, study, and daily decision-making.

The neurophysiological findings were more selective, and that selectivity is what makes them compelling. Of the five TMS-evoked components examined, only one distinguished the groups: the N100, a negative-going deflection appearing roughly one hundred milliseconds after stimulation. Patients with depression showed a significantly larger N100 magnitude at the F3 electrode than healthy controls, while the earlier and later components, P30, N45, P60, and P180, did not differ between the groups. This pattern suggests that the alteration in depression is not a blanket change in cortical responsiveness but a specific modification of the mid-latency inhibitory processing that the N100 is thought to reflect, a component widely associated with GABAergic inhibitory mechanisms in the stimulated cortex.

The most striking result emerged when the researchers looked within the patient group. A more negative N100 amplitude was associated with poorer sustained-attention performance, measured with the Continuous Performance Test, and this correlation survived correction for multiple comparisons using the false discovery rate procedure. In other words, the strength of the brain’s electrical response to direct prefrontal stimulation predicted how well a patient could maintain focus over time. The association was specific enough that the other TEP components did not show the same relationship, hinting that the N100 carries information about a particular cognitive function rather than general brain health.

Skeptics might wonder whether the link simply reflects mood severity, anxiety, or demographic differences rather than a genuine neurocognitive relationship. The research team anticipated this concern and tested it directly with hierarchical multiple linear regression. After statistically adjusting for depressive symptom severity, anxiety symptoms, age, sex, and years of education, the association between N100 amplitude and sustained-attention performance remained significant. This robustness matters because it suggests the N100 is not merely a proxy for how depressed someone feels on the day of testing; it appears to index something about prefrontal cortical function that is tied to attentional capacity in its own right, independent of the clinical and demographic factors that often confound such studies.

The authors also took care to address the possible influence of medication. Supplementary analyses compared patients who were medication-free with those taking antidepressants, and separately with those treated with benzodiazepines, examining both clinical characteristics and TEP amplitudes across these subgroups. Quality metrics for the TMS-EEG preprocessing, resting motor threshold, and stimulation intensity were likewise compared between groups to ensure that the group difference in N100 was not an artifact of differing recording conditions or stimulation parameters. These controls strengthen the case that the observed alteration reflects genuine neurophysiological differences associated with the disorder rather than technical or pharmacological confounds, although the authors are careful to note that the findings require longitudinal validation before the N100 can be considered a clinically useful marker.

Why should this matter beyond the laboratory? First, it provides an objective, physiology-based correlate of cognitive dysfunction in depression, a field that has long relied on subjective reports and behavioral testing alone. A measurable electrical signature recorded in a single session could, with further validation, help clinicians identify which patients carry the greatest cognitive burden, track changes over the course of illness or treatment, and potentially guide neuromodulation therapy by revealing how responsive a patient’s prefrontal cortex is before a treatment course begins. Second, the specificity of the N100-sustained attention link offers a mechanistic clue: it points toward altered inhibitory processing in the left dorsolateral prefrontal cortex as a candidate contributor to the attentional failures that so many patients describe, connecting a cellular-level hypothesis about GABAergic function to a real-world symptom.

The study’s limitations are acknowledged by its authors and deserve emphasis. The design was cross-sectional, meaning it captured a single moment in time and cannot establish whether the altered N100 causes attentional impairment, results from it, or both reflect a shared underlying process. The patient group was heterogeneous in medication status, and while the supplementary analyses addressed this, larger samples will be needed to disentangle drug effects definitively. The authors themselves state that the functional specificity and clinical utility of the F3-recorded N100 require longitudinal validation. Even so, the work represents a meaningful step toward grounding the cognitive symptoms of depression in measurable brain physiology. For the millions of people whose depression is defined as much by foggy thinking and wandering focus as by low mood, the prospect of an objective marker, and eventually a targeted way to monitor and treat cognitive dysfunction, is a development worth watching closely.

Subject of Research: Neurophysiological markers of executive dysfunction in major depressive disorder using TMS-evoked potentials from the left dorsolateral prefrontal cortex

Article Title: Association between executive function and left dorsolateral prefrontal TMS-evoked potentials in major depressive disorder

Article References: Zhang, J.-Q., Zhang, H.-G., An, Q., Cao, M.-N., Deng, W.-Y., Jing, W.-T., Zhao, J.-H., Xue, C., Sun, J.-J., & Deng, W. (2026). Association between executive function and left dorsolateral prefrontal TMS-evoked potentials in major depressive disorder. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08646-1

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08646-1

Keywords: major depressive disorder, executive function, TMS-EEG, TMS-evoked potentials, dorsolateral prefrontal cortex, sustained attention, N100, neurophysiology, cognitive dysfunction, neuromodulation, psychiatry, prefrontal cortex